2024:
1. Wu, J., Wu, W., Zhou, B., and Li, B.* Chimeric antigen receptor therapy meets mRNA technology. Trends in Biotechnology. 42, 228 (2024). (Featured Article by Trends in Biotechnology; IF 17.3) PDF
2. Huang, Y., Wu, J., Li, S., Liu, Z., Li, Z., Zhou, B., and Li, B.* Quaternization drives spleen-to-lung tropism conversion for mRNA-loaded lipid-like nanoassemblies. Theranostics. 14, 830 (2024). (IF 12.4) PDF
2023:
1. Li, M., Huang, Y., Wu, J., Li, S., Mie, M., Chen, H., Wang, N., Wu, W., Zhou, B., Tan, X., and Li, B.* A PEG-lipid-free COVID-19 mRNA vaccine triggers robust immune responses in mice. Mater. Horiz. 10, 466 (2023). (Materials Horizons HOT Papers; Highlighted in the "mRNA vaccines against COVID-19: Celebrating the 2023 Nobel Prize in Physiology or Medicine" Collection; IF 15.7) Link
2022:
1. Li, Z., Li, Z., Wu, J., and Li, B.* Cell-derived vesicles for mRNA delivery. Pharmaceutics 14, 2699 (2022). (IF 6.5) PDF
2. Huang, Y., Yang, M., Wang, N., Li, S., Liu, Z., Li, Z., Ji, Z.*, and Li, B.* Intracellular delivery of messenger RNA to macrophages with surfactant-derived lipid nanoparticles. Mater. Today Adv. 16, 100295 (2022). (IF 9.9) PDF
3. Liu, Z., Li, Z., and Li, B.* Nonviral delivery of CRISPR/Cas systems in mRNA format. Adv. Nanobiomed. Res. 2, 2200028 (2022). Link
2021:
1. Li, M., Li, S., Huang, Y., Chen, H., Zhang, S., Zhang, Z., Wu, W., Zeng, X., Zhou, B., and Li, B.* Secreted expression of mRNA-encoded truncated ACE2 variants for SARS-CoV-2 via lipid-like nanoassemblies. Adv. Mater. 33, 2101707 (2021). (IF 30.8) PDF
2020:
1. Li, B., Yan, J., Zhang, Y., Li, W., Zeng, C., Zhao, W., Hou, X., Zhang, C., and Dong, Y. CRISPR-Cas12a possesses unconventional DNase activity that can be inactivated by synthetic oligonucleotides. Mol. Ther. Nucleic Acids. 19, 1043-1052 (2020). (IF 7.0) PDF
2. Li, B., Niu, Y., Ji, W., and Dong, Y. Strategies for the CRISPR-based therapeutics. Trends Pharmacol. Sci. 41, 55–65 (2020). (IF 13.5) PDF
2019:
1. Zhang, Y., Zhang X., Zeng, C., Li, B., Zhang, C.., Li, W., Hou, X., Dong, Y.. Targeted delivery of atorvastatin via asialoglycoprotein receptor (ASGPR). Bioorg. Med. Chem. 27, 2187-2191 (2019). (IF 3.1) PDF
Publications before 2019:
1. Li, B., Zhao, W., Luo, X., Zhang, X., Li, C., Zeng, C., and Dong, Y. Engineering CRISPR-Cpf1 crRNAs and mRNAs to maximize genome editing efficiency. Nat. Biomed. Eng. 1, 0066 (2017). (IF 19.0) PDF
2. Li, B., Zeng, C., and Dong, Y. Design and assessment of engineered CRISPR–Cpf1 and its use for genome editing. Nat. Protoc. 13, 899–914 (2018). (IF 10.4) PDF
3. Jiang, C.#, Mei, M.#, Li, B.#, Zhu, X.#, Zu, W., Tian, Y ., Wang, Q., Guo, Y ., Dong, Y ., and Tan, X. A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo. Cell Research 27, 440–443 (2017). (IF 20.5) PDF
4. Li, B., Luo, X., Deng, B., Wang, J., McComb, D.W., Shi, Y ., Gaensler, K.M., Tan, X., Dunn, A.L., Kerlin, B.A., and Dong, Y. An orthogonal array optimization of lipid-like nanoparticles for mRNA delivery in vivo. Nano Lett. 15, 8099–8107 (2015). (IF 11.2) PDF
5. Li, B., Zeng, C., Zhang, X., Luo, X., Zhao, W., Zhang, C., and Dong, Y. Synthetic oligonucleotides inhibit CRISPR-Cpf1 mediated genome editing. Cell Rep. 25, 3262–3272 (2018). (IF 8.1) PDF
6. Zhang, X.#, Li, B.#, Luo, X.#, Zhao, W., Jiang, J., Zhang, C., Gao, M., Chen, X., and Dong, Y. Biodegradable amino-ester nanomaterials for Cas9 mRNA delivery in vitro and in vivo. ACS Appl. Mater. Interfaces 9, 25481–25487 (2017). (IF 8.8) PDF
7. Li, B., Zhang, X. and Dong, Y. Nanoscale platforms for messenger RNA delivery. WIREs Nanomed. Nanobiotechnol. 11, e1530 (2019). (IF 7.7) PDF
8. Li, B., Liu, X.J., Li, L., Zhang, S.H., Li, Y ., Li, D.D., and Zhen, Y .S. A tumortargeting dextran–apoprotein conjugate integrated with enediyne chromophore shows highly potent antitumor efficacy. Polym. Chem. 5, 5680–5688 (2014). (IF 5.3) PDF
9. Li, B., Luo, X., and Dong, Y. Effects of chemically modified messenger RNA on protein expression. Bioconjug Chem. 27, 849–853 (2016). (IF 4.0) PDF
11. Li, B., Zheng, Y .B., Li, D.D., and Zhen, Y .S. Preparation and evaluation of a CD13/APN-targeting and hydrolase-resistant conjugate that comprises pingyangmycin and NGR motif-integrated apoprotein. J Pharm Sci. 103, 1204–1213 (2014). (IF 3.0) PDF
12. Li, B., Zhao, W., Zhang, X., Wang, J., Luo, X., Baker, S.D., Jordan, C.T., and Dong, Y. Design, synthesis and evaluation of anti-CD123 antibody drug conjugates. Bioorg. Med. Chem. 24, 5855–5860 (2016). (IF 3.1) PDF
13. Li, B., Chen, G., Bai, J., Jing, Y.K. and Pei, Y .H. A bisamide and four diketopiperazines from a marine-derived Streptomyces sp. J Asian Nat Prod Res. 13, 1146–1150 (2011). (IF 1.3) PDF
14. Zhang, X.1, Zhao, W.1, Li, B., Li, W., Zhang, C., Hou, X., Jiang, J. and Dong Y. Ratiometric fluorescent probes for capturing endogenous hypochlorous acid in the lungs of mice. Chem. Sci. 9, 8207-8212 (2018). (IF 9.3) PDF
15. Luo, X., Zhao, W., Li, B., Zhang, X., Zhang, C., Bratasz, A. Deng, B. David W. McComb, D.W., and Dong Y. Co-delivery of mRNA and SPIONs through aminoester nanomaterials. Nano Res. 11, 5596-5603 (2018). (IF 8.2). PDF
16. Zhang, C.#, Zhang, X.#, Zhao, W.#, Zeng, C., L, W., Li, B., Luo, X., Li, J., Jiang, J., Binbin Deng, B., McComb, D.W. and Dong Y. Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast cancer. Nano Res. (2019). (IF 8.2). PDF
17. Luo, X., Li, B., Zhang, X., Zhao, W., Bratasz, A., Deng, B., McComb, D.W., and Dong, Y. Dual-functional Lipid-like Nanoparticles for Delivery of mRNA and MRI Contrast Agent. Nanoscale 9, 1575–1579 (2017). (IF 6.9). PDF
18. Wang, J., Li, B., Zhao, W., Zhang, X., Luo, X., Corkins, M.E., Cole, S.L., Wang, C., Xiao, Y ., Bi, X., Pang, Y ., McElroy, C.A., Bird, A.J., and Dong, Y. Two-photon near infrared fluorescent turn-on probe toward cysteine and its imaging applications, ACS Sens. 1, 882–887 (2016). (IF 7.3) PDF
19. Zhang, X.#, Chen, X.#, Zhao, W., Zeng, C., Li, B., Jiang, J., and Dong, Y. GlcNAc conjugated atorvastatin with enhanced water solubility and cellular internalization. Bioconjug Chem. 28, 2109–2113 (2017). (IF 4.0) PDF
20. Zhao, W., Zhang, C., Li, B., Zhang, X., Luo, X., Zeng, C., Li, W., Gao, M. and Dong Y. Lipid Polymer Hybrid Nanomaterials for mRNA Delivery. Cel. Mol. Bioeng. 11, 397-406 (2018). (IF 1.7) PDF
21. 李斌, 郑艳波, 李良, 甄永苏. 基于抗体和配体的肿瘤靶向肽药物研究进展[J]. 中国医药生物技术. 9, 294–299 (2014). PDF
22. 李斌, 陈刚, 白皎, 裴月湖. 海洋放线菌Streptomyces sp. 次级代谢产物的研究[J]. 中国药物化学杂志. 21, 227–231 (2011). PDF
Book Chapter:
1. Li B., Dong Y. (2017) Preparation and Optimization of Lipid-Like Nanoparticles for mRNA Delivery. In: Bindewald E., Shapiro B. (eds) RNA Nanostructures. Methods in Molecular Biology, vol 1632. Humana Press, New York, NY. PDF
Projects:
1. 深圳市优秀科技创新人才培养优秀青年基础研究，2021/04-2024/04，200万元，主持。
2. 国家自然科学基金面上项目，2021/01-2024/12，58万元，主持。
3. 深圳市科技创新委员会基础研究面上项目，2020/05/21-2023/05/31，10万元，主持。
4. 广东省第一批高水平医院建设「登峰计划」医院人才引进科研启动经费，2019/05/13-2024/05/13，800万元，主持。
5. National Heart, Lung, and Blood Institute (NHLBI)，2017/04/01-2022/03/31，37.88万美元，参与。
6. National Institute of General Medical Sciences，2016/08/01-2021/05/31，34.65万美元，参与。
7. 中华人民共和国科学技术部重大新药创制国家科技重大专项，2013/01-2015/12，594万元，参与。
Patent:
1. 李斌，李敏，李三朋，黄逸轩，吴伟刚，王宁。一种编码SARS-CoV-2 抗原的mRNA及mRNA疫苗，中国发明专利CN202111300838.9 (授权).
2. 李斌，李三朋，黄逸轩，李敏，吴伟刚，吴嘉彩。一种mRNA递送系统及其制备方法和应用，国际发明专利PCT/CN2021/128358.
3. 李斌，李三朋，李敏，黄逸轩。一种mRNA递送系统及其制备方法和应用，中国发明专利ZL202111154524.2 (授权).
4. 李斌，李三朋，黄逸轩，李敏，吴伟刚，吴嘉彩。一种mRNA递送系统及其制备方法和应用，中国发明专利ZL202111114926.X (授权).
5. 李斌，李三朋，李敏，黄逸轩，吴伟刚。一种脂质分子、脂质纳米粒及其制备方法及其应用，中国发明专利ZL202110637314.2 (授权).
6. 李斌，李敏，李三朋，黄逸轩，吴伟刚。一种编码分泌型血管紧张素转换酶2的mRNA及其应用，中国发明专利CN202110552971.7 (授权).
7. Dong, Y., and Li, B. Benzene-1,3,5-tricarboxamide derivatives and uses thereof. 美国发明专利US10369122 (授权).
8. Dong, Y., and Li, B. Engineered guide NRA and uses thereof. 美国发明专利US20190241911A1.
9. Dong, Y., and Li, B. Modified nucleic acids, hybrid guide RNA, and uses thereof. 美国发明专利US20200056167A1.
10. Dong, Y., and Li, B. Modified Cpf1 mRNA, modified guide RNA, and uses thereof. 美国发明专利US20200172935A1.
11. 李斌，李三朋，李敏，黄逸轩。一种脂样分子及其应用，中国发明专利202011593317.2
12. 谭旭，董一洲，蒋超，梅淼，祖文红，李斌。PCSK9抑制剂类降血脂药的递送系统和生物制剂，中国发明专利201710065450.2.
